Investigational drug · Phase 2
Gecacitinib
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lymphoma, Non-small Cell Lung Cancer, Advanced Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
18
Any phase or sponsor naming "Gecacitinib"
First trial start
2025
May 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Gecacitinib", any sponsor or status.
- Phase 213
Conditions studied
As listed on its trial records.
- Lymphoma
- Non-small Cell Lung Cancer
- Advanced Solid Tumor
- Cervical Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Cervical cancer · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Gecacitinib" as an intervention, largest first.
- Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsPivotal-lookingNot yet recruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07142837 · 153 participants (planned) · Start Sep 2025 · Primary completion Oct 2027
Drug: ZG005; Gecacitinib · For: Advanced Solid Tumor
Sites: Beijing, China
- Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerPivotal-lookingRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07080216 · 120 participants (planned) · Start Sep 23, 2025 · Primary completion Aug 2027
Drug: ZG005; Gecacitinib and 1 more · For: Cervical Cancer
Sites: Hangzhou, China
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07454226 · 92 participants (planned) · Start May 30, 2026 · Primary completion Mar 1, 2028
Drug: Olverembatinib; Gecacitinib and 3 more · For: Ph-Like; Acute Lymphoblastic Leukemia
Sites: Tianjin, China
- A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.Active, not recruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07565597 · 64 participants · Start May 12, 2026 · Primary completion Feb 2027
Drug: Gecacitinib Hydrochloride Tablets · For: Healthy
Sites: Changsha, China
- Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06883526 · 60 participants (planned) · Start May 16, 2025 · Primary completion Apr 2027
Drug: ZG005 for Injection; Gecacitinib Hydrochloride Tablets · For: Lymphoma
Sites: Hangzhou, China
- Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06903377 · 50 participants (planned) · Start May 23, 2025 · Primary completion Apr 2027
Drug: ZG005 for Injection; Gecacitinib Hydrochloride Tablets · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
- Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruiting
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT07904871 · 46 participants (planned) · Start Nov 1, 2026 · Primary completion Nov 1, 2028
Drug: Peri-Transplant Gecacitinib · For: Myelofibrosis; Primary Myelofibrosis (PMF); Secondary Myelofibrosis
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT07440654 · 40 participants (planned) · Start Mar 1, 2026 · Primary completion Sep 1, 2029
Drug: Gecacitinib · For: aGVHD Prophylaxis
- Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary MyelofibrosisNot yet recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07471503 · 39 participants (planned) · Start Mar 16, 2026 · Primary completion Apr 1, 2029
Drug: Gecacitinib (also known as Jaktinib) · For: Myelofibrosis (MF); HSCT
- Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular CarcinomaNot yet recruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT07157306 · 35 participants (planned) · Start Sep 10, 2025 · Primary completion Jan 1, 2027
Drug: Gecacitinib Combined With Donafenib and PD-1 Inhibitor · For: Hepatocellular Carcinoma
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy Versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients.
Zhang Y, Zhou H, Zhuang J, et al. · Clin Lymphoma Myeloma Leuk 2026
- [Gecacitinib as a bridging treatment to allogeneic hematopoietic stem cell transplantation for high-risk myelodysplastic syndrome with Behçet's syndrome: a case report].
Wu W, Mu GF, Zhu HM, et al. · Zhonghua Nei Ke Za Zhi 2026
- Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.
Zhang Y, Zhou H, Zhang Q, et al. · Hematol Oncol 2026
- Population Pharmacokinetics of Oral Gecacitinib in Healthy Subjects and Patients with Autoimmune and Inflammatory Diseases.
Meng Q, Zhao Y, Chen W, et al. · J Clin Pharmacol 2026
- Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.
Zhang Y, Zhou H, Suo S, et al. · Blood Cancer J 2024
Also in development for Lymphoma
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- OSE2101Phase 32 trials
OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma
- AZD3470Phase 22 trials
AstraZeneca · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
- COH04S1GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Phase 22 trials
GeoVax, Inc. · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia
- ASTX660Phase 21 trial
Taiho Oncology, Inc. · Solid Tumors, Lymphoma
- BT02Phase 21 trial
Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma
- CTS3497Phase 21 trial
CytosinLab Therapeutics Co., Ltd. · Solid Tumor, Lymphoma
- EB103Phase 21 trial
Estrella Immunopharma, Inc. · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.